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Introduction
Unprovoked venous thromboembolism (VTE) may be the first manifestation of an
undiagnosed cancer. We assessed the cost-effectiveness of 18F-Fluorodesoxyglucose
Positron Emission/Computed Tomography (FDG PET/CT) plus limited screening and
limited screening strategies in patients with unprovoked VTE from the perspectives
of the Ontario (Canada) and French health care systems.
Methods
We conducted a cost-effectiveness analysis based on a published randomized
controlled trial of 394 patients aged 18 years or older who were diagnosed with
unprovoked VTE. We obtained data with respect to efficacy and health care
utilization from the published trial. The primary measure of effectiveness was the
number of avoided cases of delayed cancer diagnosis and the secondary measure of
effectiveness was the quality adjusted life year (QALY) at the end of the study in
each group. We used generalized linear models to estimate incremental cost-
effectiveness ratios (ICER) while controlling for patient demographic and clinical
characteristics. Results were presented as the incremental cost to avoid one case of
delayed cancer diagnosis and the incremental cost per QALY gained. The 95%
confidence intervals (CIs) were estimated using bootstrap re-sampling procedures
with 5000 iterations.
Results
Compared to a limited screening strategy, the ICER of limited strategy plus FDG
PET/CT scan was C$ 26,840.19 (95% CI: C$ 24,046.51; C$ 34,581.53) per one
avoided case of delayed cancer diagnosis from the Ontario health system perspective
and €16,370.45 (95% CI: € 9904.48; € 39,578.91) per one avoided case of delayed
cancer diagnosis from the French health system perspective. The probabilities that
addition of FDG PET/CT to limited screening is cost-effective rose with increasing
willingness to pay values. Compared with the limited screening, the extensive
screening was associated with C$ 3412.85 per QALY gained (95% CI: 1463.89;
−13,935.88) from the Ontario health system perspective and €2162.83 per QALY
gained (95% CI 958.78; −10,544.42) from the French health system perspective.
Conclusion
Addition of a FDG PET/CT for occult cancer diagnosis was associated with better
health outcomes (fewer cases of delayed cancer diagnosis and greater QALYs) and a
higher cost from the perspective of publicly funded health care systems; the cost-
effectiveness results are however highly uncertain.
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